

1995

Albini A., Barillari G., Benelli R., Gallo R.C., and Ensoli B. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. *Proc. Natl. Acad. Sci. USA*, 92:4838-4842, 1995.

Chang H.K., Gallo R.C., and Ensoli B. Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 Tat protein. *J. Biomed. Sci.*, 2:189-202, 1995.

Chelucci C., Hassan H.J., Locardi C., Bulgarini D., Pelosi E., Mariani G., Testa U., Federico M., Valtieri M., and Peschle C. *In vitro* human immunodeficiency virus-1 infection on purified hematopoietic progenitors in single-cell culture. *Blood*, 85:1181-1187, 1995.

de Lellis L., Fabris M., Cassai E., Corallini A., Giraldo G., Feo C., and Monini P. Herpesvirus-like DNA sequences in non-AIDS Kaposi's sarcoma. *J. Infect. Dis.*, 172:1065-1067, 1995.

Di Luca D., Mirandola P., Ravaioli T., Dolcetti R., Frigatti A., Bovenzi P., Sighinolfi L., Monini P., and Cassai E. Human herpesvirus 6 and 7 in salivary glands and shedding in saliva of healthy and human immunodeficiency virus positive individuals. *J. Med. Virol.*, 45:462-468, 1995.

Ensoli B. and Gallo R.C. AIDS-associated Kaposi's sarcoma: A new perspective of its pathogenesis and treatment. *Proc. Assoc. Am. Physicians*, 107:8-18, 1995.

Ensoli F., Cafaro A., Fiorelli V., Vannelli B., Ensoli B., and Thiele C.J. HIV-1 infection of primary neuroblasts. *Virology*, 210:221-225, 1995.

Federico M., Nappi F., Bona R., d'Aloja P., Verani P., Rossi G.B. Full expression of transfected non-producer interfering HIV-1 proviral DNA abrogates susceptibility of human He-La CD4+ cells to HIV. *Virology*, 206:76-84, 1995.

Federico M., Nappi F., Ferrari G., Chelucci C., Mavilio F., Verani P. A non-producer, interfering HIV-1 provirus can be transduced through a MLV-based retroviral vector: recovery of an anti-HIV mouse/human pseudotype retrovirus. *J. Virol.*, 69:6618-6626, 1995.

Fiorelli V., Gendelman R., Samaniego F., Markham P.D., and Ensoli B. Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells. *J. Clin. Invest.*, 95:1723-1734, 1995.

Incorvaia C., Manservigi R., Parmeggiani F., Monini P., Longhini L., Caselli E., and Cassai E. Effects of the passive transfer of Anti-gB antibodies in a rabbit model of HSV-1 induced keratitis. *Ophthalmologica*, 209:340-345, 1995.

Lisziewicz J., Sun D., Trapnell B., Thomson M., Chang H.K., Ensoli B., and Peng B. An autoregulated dual-function antitumor gene for human immunodeficiency virus type 1 gene therapy. *J. Virol.*, 69:206-212, 1995.

Mannini-Pallenzona A., Moschella A., Costanzo F., Manservigi R., and Monini P. Cell-type dependent sensitivity of herpes simplex virus 1 mutants to plaque development inhibition by an anti-gD monoclonal antibody. *Microbiologica*, 18:351-358, 1995.

Monini P., de Lellis L., Rotola A., Di Luca D., Ravaioli T., and Cassai E. Chimeric BK virus DNA episomes in a papillary urothelial bladder carcinoma. *Intervirology*, 38:304-308, 1995.

Monini P., Rotola A., Di Luca D., de Lellis L., Chiari E., Corallini A., and Cassai E. DNA rearrangements impairing BK virus productive infection in urinary tract tumors. *Virology*, 214:273-279, 1995.

Pane F., Buttò S., Gobbo M.L., Franco M., Butteroni C., Pastore L., Maiorano G., Foggia A., Tullio Cataldo P., Guarino A., Tamburrini E., Solinas S., Piazza M., Vecchio G., Verani P. and Salvatore F. Direct detection of proviral gag segment of HIV in peripheral blood lymphocytes by a colorimetric PCR assay as a clinical laboratory tool applied to different at-risk populations. *J. Clin. Microbiol.*, 33:641-647, 1995.

Samaniego F., Markham P.D., Gallo R.C., and Ensoli B. Inflammatory cytokines induce AIDS-Kaposi's sarcoma-derived spindle cells to produce and release basic fibroblast growth factor and enhance Kaposi's sarcoma-like lesion formation in nude mice. *J. Immunol.*, 154:3582-3592, 1995.

Vandendriessche T., Chuah M.K.L., Chiang L., Chang H.K., Ensoli B., and Morgan R.A. Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4⁺ T lymphocytes by retroviral vectors expressing anti-HIV genes. *J. Virol.*, 69:4045-4052, 1995.

1996

Bohan Morris C., Gendelman R., Marrogi A.J., Lu M., Lockyer J.M., Alperin-Lea W., and Ensoli B. Immunohistochemical detection of bcl-2 in AIDS-associated and classical Kaposi's sarcoma. *Am. J. Pathol.*, 148:1055-1063, 1996.

Brother M.B., Chang H.K., Lisziewicz J., Su D., Murty L.C., and Ensoli B. Block of Tat-mediated transactivation of tumor necrosis factor β gene expression by polymeric-TAR decoys. *Virology*, 222:252-256, 1996.

Cafaro A., St. Louis D.C., Levine B., Lewis M., June C.H., Di Fabio S., Titti F., Verani P., and Ensoli B. Anti-CD3/28-mediated activation of T cells in monkeys: evaluation of proliferation, SIV replication and susceptibility to virus infection. *J. AIDS and Hum. Retrov.* (Lippincott-Raven Publishers), Abstracts of the 1996 Annual Meeting of the Institute of Human Virology, Baltimore, September 7-13, 1996, Vol. 14:65.

Carlini F., A. Nicolini, P. D'Aloja, M. Federico, and P. Verani. The non-producer phenotype of the human immunodeficiency virus type 1 provirus F12/HIV-1 is the result of multiple genetic variations. *J. Gen. Virol.*, September 1996.

Ensoli B. AIDS-associated Kaposi's sarcoma pathogenesis. Role of inflammatory and angiogenic cytokines and HIV-1 Tat protein. Proceedings of "HIV and Cytokines", Reims, Guenounou M. (Ed.), Chapter 44, pp. 341-348, 1996.

Ensoli B., and Cafaro A. HIV-1 and Kaposi's sarcoma. *Eur. J. Cancer Prev.* 5:410-412, 1996.

Ensoli B., Gallo R.C., and Fiorelli V. New developments: a look to the future. *Oncology*, 10:34-36, 1996.

Faris M., Ensoli B., Stahl N., Yancopoulos G., Nguyen A., Wang S., and Nel A.E. Differential activation of the extracellular signal-regulated kinase, Jun Kinase and Janus Kinase-Stat pathways by oncostatin M and basic fibroblast growth factor in AIDS-derived Kaposi's sarcoma cells. *AIDS*, 10:369-378, 1996.

Gallo R.C., Franchini G., Ensoli B., and Colombini-Hatch S. HTLV- and HIV-associated malignancies. In Bertino, J.R. (Ed.): *Encyclopedia of Cancer*, Vol. II, San Diego, Academic Press, 1996, pp. 866-887.

Lisziewicz J., Sun D., Gallo R.C., Ensoli B., and Lori F. Efficacy of antitumor gene therapy in the presence of high multiplicity infection of inflammatory cytokines. *Human Gene Ther.*, 7:2209-2216, 1996.

Monini P., de Lellis L., and Barbanti-Brodano G. Association of BK and JC polyomaviruses and SV40 with human tumors In: *DNA Tumor Viruses: Oncogenic Mechanisms*, H. Friedman, Bendinelli M., and G. Barbanti-Brodano (Eds). New York Plenum Press, 1996.

Monini P., de Lellis L., and Cassai E. Absence of HHV-8 in prostate and semen (reply). *New Engl. J. Med.*, 335:1237-1239, 1996.

Monini P., de Lellis L., Fabris M., Rigolin F., and Cassai E. Kaposi's Sarcoma-associated Herpesvirus DNA sequences in prostate tissue and human semen. *New Engl. J. Med.*, 334:1168-1172, 1996.

Monini P., Rotola A., de Lellis L., Corallini A., Albini A., Benelli R., Parravicini C., Barbanti-Brodano G., and Cassai E. Latent BK virus infection and Kaposi's sarcoma pathogenesis. *Int. J. Cancer*, 66:717-722, 1996.

Monini, P., and Laimonis, L.A.: Modulation of epithelial differentiation by the E6 and E7 oncoproteins of human papillomavirus. *Radiation Oncol. Invest.*, 3:377-382, 1996.

Otsuki T., Kumar S., Ensoli B., Kingma D.W., Yano T., Stetler-Stevenson M., Jaffe E.S., and Raffeld M. Detection of HHV-8/KSHV DNA sequences in AIDS-associated extranodal lymphoid malignancies. *Leukemia*, 10:358-1362, 1996

Titti F., De Rossi A., Geraci A., Masiero S., Corrias F., Panzini G.L., Sernicola L., Maggiorella M.T., Fabiani M., Baroncelli S., Turillazzi G.P., Amadori A., Chieco-Bianchi L. and Verani P. Immunotherapy of SIV-infected *Macaca fascicularis* with an inactivated whole SIV immunogen. *Cell. Pharm. AIDS Sci.*, 3:269-276, 1996.

Titti F., Sernicola L., Corrias F., Borsetti A., Maggiorella M.T., Panzini G.L., Geraci A., Zamarchi R., Amadori A., Chieco-Bianchi L., Verani P. Vaccination of *Cynomolgus* monkeys with whole inactivated or live attenuated simian immunodeficiency virus. *Proceedings International Workshop on "Development and Application of Vaccines and Gene Therapy in AIDS"*. Eds. G. Giraldo, D.P. Bolognesi, M. Salvatore, E. Beth-Giraldo. In "Antibiotics and Chemotherapy", Karger, vol.48:131-138, 1996.

1997

Baiocchi M., Olivetta E., Chelucci C., Santarcangelo A.C., Bona R., d'Aloja P., Testa U., Komatsu N., Verani P., and Federico M. HIV-resistant CD4 positive UT-7 magakaryocytic human cells becomes highly HIV-1 and HIV-2 susceptible upon CXCR4 transfection: induction of cell differentiation by HIV-1 infection. *Blood*, 89:2670-2678, 1997.

Baroncelli S., Panzini G., Geraci A., Pardini S., Corrias F., Iale R., Varano F., Turillazzi PG., Titti F., Verani P. Longitudinal characterization of CD4, CD8 T-cell subsets and of haematological parameters in healthy newborns of cynomolgus monkeys. *Vet. Immunol. Immunopath.*, 57:141-150, 1997.

Blasig C., Zietz C., Haar B., Neipel F., Esser S., Brockmeyer N.H., Tschachler E., Colombini S., Ensoli B., Stürzl M. Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8. *J. Virol.*, 71:7963-7968, 1997.

Bona R., d'Aloja P., Olivetta E., Modest A., Modica A., Geraci A., Ferrari G., Verani P., and Federico M. Aberrant non infectious HIV-1 particles are released by chronically infected human T cells transduced with a retroviral vector expressing an interfering HIV-1 variant. *Gene Ther.*, 4:1085-1092, 1997.

Buttò S., Argentini C., Mazzella A.M., Iannotti M.P., Leone P., Leone P., Nicolosi A. and Rezza G. Dual infection with different strains of the same HIV-1 subtype. *AIDS*, 11: 694-696, 1997.

Chang H.C., Samaniego F., Nair B.C., Buonaguro L., and Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. *AIDS*, 11:1421-1431, 1997.

Monini P., Howard M.R., Rimessi P., de Lellis L., Schulz T.F., Cassai E. Human herpesvirus DNA in prostate and semen from HIV-negative individuals in Italy. *AIDS*, 11:1530-1532, 1997.

Rozera C., Baccarini S., Gentile M., Torrisi M.R., Proietti E., Federico M., Pulciani S. Stable transfection of provirus of human immunodeficiency virus into a murine packaging cell line. *Acta Virologica*, 41:105-110, 1997.

Samaniego F., Markham P.D., Gendelman R., Gallo R.C., and Ensoli B. Inflammatory cytokines induce endothelial cells to produce and release basic fibroblast growth factor and to promote Kaposi's sarcoma-like lesions in nude mice. *J. Immunol.*, 158:1887-1894, 1997.

Sirianni M.C., Uccini S., Angeloni A., Faggioni A., Cottoni F., and Ensoli B. Circulating spindle cells: correlation with human herpesvirus-8 (HHV-8) infection and Kaposi's sarcoma. *The Lancet*, 349:255, 1997.

Strumia R., Roveglio C., Rotola A., Monini P., and Cassai E. Keratoacanthomas: human papillomavirus and herpes simplex virus associated? *J. Eur. Acad. Dermatol. Venereol.*, 8:130-136, 1997.

Titti F., Sernicola L., Geraci A., Panzini G., Di Fabio S., Belli R., Monardo F., Borsetti A., Maggiorella M.T., Koanga-Mogtomo M.L., Corrias D., Zamarchi R., Amadori A., Chieco-Bianchi L., and Verani P. Live attenuated simian immunodeficiency virus prevents superinfection by cloned SIVmac251 in cynomolgus monkeys. *J. Gen. Virol.*, 78: 2529-2539, 1997.

Verani P., Titti F., Corrias F., Belli R., Di Fabio S., Geraci A., Koanga-Mogtomo M.L., Maggiorella M.T., and Sernicola L. Vaccines against HIV. *J. Biol. Reg. and Homeost. Agents*, 11: 82-87,1997.

1998

Barillari G., Albonici L., Franzese O., Modesti A., Liberati F., Barillari P., Ensoli B., Manzari V., and Santeusano G. The basic residues of placenta growth factor type 2 retrieve sequestered angiogenic factors into a soluble form. *Am. J. Pathol.*, 152:1161-1166, 1998.

Biberfeld P., Ensoli B., Stürzl M., and Schulz T.F. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8, cytokines, growth factors and HIV in pathogenesis of Kaposi's sarcoma. *Curr. Opin. Infect. Dis.*, 11:97-105, 1998.

Chelucci C., Federico M., Guerriero R., Mattia G., Casella I., Pelosi E., Testa U., Mariani G., Hassan H.J., and C. Peschle. Productive Human Immunodeficiency virus-1 infection of purified megakaryocytic progenitors/precursors and maturing megakaryocytes. *Blood*, 94:1225-1234, 1998.

D'Aloja P., Olivetta E., Bona R., Nappi F., Pedacchia D., Pugliese K., Ferrari G., Verani P. and Federico M. Gag, Vif and Nef genes contribute to the homologous viral interference induced by a non-producer human immunodeficiency virus type-1 (HIV-1) variant: identification of novel HIV-1 inhibiting viral protein mutants *J. Virol.* 72:4308-4319, 1998.

Di Fabio S., Medaglini D., Rush C., Corrias F., Panzini G., Pace M., Verani P., Pozzi G., Titti F. Vaginal immunization of Cynomolgus monkeys with *Streptococcus gordonii* expressing HIV-1 and HPV 16 antigens. *Vaccine*, 16:485-492, 1998.

Di Fabio S., Trabattoni D., Geraci A., Ruzzante S., Panzini G., Fusi M.L., Chiarotti F., Corrias F., Belli R., Verani P., Dalgleish A., Clerici M., and Titti F. Effects of thalidomide therapy in symptomatic simian immunodeficiency virus-infected cynomolgus. *AIDS*, 12:334, 1998.

Ensoli B. Kaposi's sarcoma pathogenesis: role for cytokines, HIV-1 Tat protein and HHV-8 infection. (XIII Congress of the Italian Society of Immunopharmacology, September 9-11, 1998, Pavia, Italy) *Haematologica* (Meeting Supplement, Supplement n. 9) 83:1-5, 1998.

Ensoli B. KS pathogenesis: role of cytokines, HIV-1 Tat protein and HHV-8 infection. Euro-Shaks, European Study on HIV associated Kaposi's sarcoma (Workshop), Barcelona, June 4-5, 1998, pp. 51-66.

Ensoli B., and Monini P. Patogenesi del sarcoma di Kaposi. In "AIDS 1998. Il contributo italiano", eds. PICCIN, pp. 385-394, 1998.

Ensoli B., and Sirianni M.C. Kaposi's sarcoma pathogenesis: a link between immunology and tumor biology. *Critical Rev. Oncogenesis*, 9:107-124, 1998.

Ensoli B., and Stürzl M. Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. (Eds. M. Sporn and J.T. Vilcek) *Cytokine and Growth Factor Reviews*, 9:63-83, 1998.

Ensoli B., Monini P., Colombini S., Goletti D., Cafaro A., Buttò S., Sgadari C., Leone P., Franco M., Leone P., Stürzl M., and Verani P. Role of HHV-8 in the pathogenesis of Kaposi's Sarcoma. (Paper presented at the Workshop of the Italian Society for Experimental Hematology, SIES, July 3rd, 1997, Florence, Italy) *Haematologica*, 83: 467-468, 1998.

Ensoli F., Fiorelli V., Vannelli B., Barni T., De Cristofaro M., Ensoli B., and Thiele C. Basic fibroblast growth factor (bFGF) supports human olfactory neurogenesis by autocrine/paracrine mechanisms. *Neuroscience*, 86:881-893, 1998.

Faris M., Ensoli B., Kokot N., and Nel A.E. Inflammatory cytokines induce the expression of fibroblast growth factor (bFGF) isoforms required for the growth of Kaposi's sarcoma and endothelial cells through the activation of AP-1 response elements in the bFGF promoter. *AIDS*, 12:19-27, 1998.

Fiorelli V., Gendelman R., Sirianni M.C., Chang H.K., Colombini S., Markham P.D., Monini P., Sonnabend J., Pintus A., Gallo R.C., and Ensoli B. γ -interferon produced by CD8⁺ T cells infiltrating Kaposi's sarcoma induces spindle cells with angiogenic phenotype and synergy with Human Immunodeficiency Virus-1 Tat protein: an immune response to Human Herpes Virus-8 infection? *Blood*, 91:956-967, 1998.

Indraccolo S., Feroli F., Minuzzo S., Mion M., Rosato A., Zamarchi R., Titti F., Verani P., Amadori A. and Chieco-Bianchi L. DNA immunization of mice against SIVmac239 gag and env using rev-independent expression plasmids. *AIDS Res. Hum. Retr.*, 14:83-90, 1998.

Kelly G.D., Ensoli B., Gunthel C. J., and Offermann M.K. Purified Tat induces inflammatory response genes in Kaposi's sarcoma cells. *AIDS*, 12:1753-1761, 1998.

Maggiorella M.T., Monardo F., Koanga-Mogtomo M.L., Cioè L., Sernicola L., Corrias F., Baroni C.D., Verani P. and Titti F. Detection of infectious simian immunodeficiency virus in B- and T-cell lymphomas of experimentally infected macaques. *Blood*, 91:3103-3111, 1998.

Medaglini D., Maggi T., Sestini P., Di Fabio S., Pace M., Titti F., Oggioni M.R., Pozzi G. Mucosal vaccine delivery in the female genital tract by recombinant Gram-positive bacteria. *Periodicum biologorum*, 100:1-6, 1998.

Pontesilli O., Guerra E.C., Ammassari A., Tomino C., Carlesimo M., Antinori A., Tamburrini E., Prozzo A., Seeber A.C., Vella S., Ortona L., Aiuti F. and The VaxSyn Protocol Team (Bucciardini R., Buttò S., Muzzi R., De Luca A., Pinter E., Ricci G., Tiracchia V., Mezzaroma I., Smith G.E.). Phase II controlled trial of post-exposure immunization with recombinant gp 160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. *AIDS*, 12:473-480, 1998.

Rezza G., Lennette E.T., Giuliani M., Pezzotti P., Caprilli F., Monini P., Buttò S., Lodi G., Di Carlo A., Levy J.A., and Ensoli B. Prevalence and determinants of anti-lytic and anti-latent antibodies to human herpesvirus-8 among Italian individuals at risk of sexually and parenterally transmitted infections. *Int. J. Cancer*, 77:361-365, 1998.

Rizzardini G., Trabattoni D., Saresella M., Piconi S., Lukwiya M., Declich S., Fabiani M., Ferrante P., Clerici M. for the Italian-Ugandan AIDS cooperation program. (Buttò S., Zanchetta N., Blé C., Zagliani A., Biasin M., Milazzo F., Greco D., Ensoli B., and Corti P.). Immune activation in HIV-infected African individuals. *AIDS*, 12:2387-2396, 1998.

Samaniego F., Markham P.D., Gendelman R., Watanabe Y., Kao V., Kowalski K., Sonnabend J.A., Pintus A., Gallo R.C., and Ensoli B. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. *Am. J. Pathol.*, 152:1433-1443, 1998.

Sirianni M.C., Vincenzi L., Fiorelli V., Topino S., Scala E., Uccini S., Angeloni A., Faggioni A., Cerimele D., Cottoni F., Aiuti F., and Ensoli B. γ -interferon production in peripheral blood mononuclear cells and tumor infiltrating lymphocytes from Kaposi's sarcoma patients: correlation with the presence of human herpesvirus-8 in peripheral blood mononuclear cells and lesional macrophages. *Blood* 91:968-976, 1998.

Sirianni M.C., Vincenzi L., Topino S., and Ensoli B. Production of human cytokines and β chemokines in AIDS-Kaposi's sarcoma patients. In Monduzzi Eds., *International Proceedings Division 12th World AIDS Conference, Geneva (Switzerland), June 28 – July 3, 1998*, pp. 99-103.

Stürzl M., Blasig C., Opalenik S.R., Ensoli B., and Browning P.J. Expression of the human herpesvirus 8 encoded viral macrophage inflammatory protein-1 gene in Kaposi's sarcoma lesions. *AIDS*, 12:1105-1106, 1998.

1999

Andreoni M., El-Sawaf G., Rezza G., Ensoli B., Nicastrì E., Ventura L., Ercoli L., Sarmati L., and Rocchi G. High seroprevalence of antibodies to Human Herpesvirus-8 in Egyptian children: evidence of nonsexual transmission. *J. Natl. Cancer Inst.*, 91:465-469, 1999.

Ascherl G., Hohenadl C., Monini P., Zietz C., Browning P.J., Ensoli B., and Stürzl M. Expression of human herpesvirus-8 (HHV-8) encoded pathogenic genes in Kaposi's sarcoma (KS) primary lesions. *Adv. Enzyme Reg.*, 39:331-339, 1999.

Ascherl G., Hohenadl C., Schatz O., Shumay E., Bogner J., Eckhart L., Tschachler E., Monini P., Ensoli B., and Stürzl M. Infection with Human Immunodeficiency Virus-1 increases expression of vascular endothelial cell growth factor in T cells: implications for acquired immunodeficiency syndrome-associated vasculopathy. *Blood*, 93:4232-4241, 1999.

Barillari G., Sgadari C., Fiorelli V., Samaniego F., Colombini S., Manzari V., Modesti A., Nair B.C., Cafaro A., Stürzl M., and Ensoli B. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the $\alpha 5\beta 1$ and $\alpha v\beta 3$ integrins by mobilizing sequestered basic fibroblast growth factor. *Blood*, 94:663-672, 1999.

Barillari G., Sgadari C., Palladino C., Gendelman R., Caputo A., Bohan Morris C., Nair B.C., Markham P., Nel A., Stürzl M., and Ensoli B. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and $\alpha v\beta 3$ integrin. *J. Immunol.*, 163:1929-1935, 1999.

Baroncelli S., Koanga-Mogtomo M.L., Michelini Z., Macchia I., Corrias F., Catone S., Belli R., Incitti F., Baroni C.D., Verani P., Titti F. Pentavalent MVA-SIV vaccine in cynomolgus monkeys: suppression of primary infection, but absence of sterilizing protection after challenge with SIVmac251. The Fourth European Conference on Experimental AIDS Research. ECEAR, Tampere (Finlandia) 18-21 June, 1999, 23-27, Monduzzi Editore, 1999.

Buttò S. and Tripiciano A. Diagnosi di laboratorio dell'infezione da HIV e follow-up del soggetto esposto al virus. In "HIV e counselling", Bravi E. e Serpelloni G Eds. La Grafica Edizioni. Capitolo 3: 51-68, October 1999.

Chelucci C., Casella I., Federico M., Testa U., Macioce G., Pelosi E., Guerriero R., Mariani G., Giampaolo A., Hassan H.J., and Peschle C. Lineage-specific expression of Human Immunodeficiency Virus (HIV) receptor/coreceptors in differentiating hematopoietic precursors: correlation with susceptibility to T- and M-tropic HIV and chemokine-mediated HIV resistance. *Blood*, 94:1590-1600, 1999.

Cafaro A., Caputo A., Fracasso C., Maggiorella M.T., Goletti D., Baroncelli S., Pace M., Sernicola L., Koanga-Mogtomo M.L., Betti M., Borsetti A., Belli R., Åkerblom L., Corrias F., Buttò S., Heeney J., Verani P., Titti F., and Ensoli B. Control of SHIV89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. *Nat. Med.*, 5:643-650, 1999.

Caselli E., Betti M., Grossi M.P., Balboni P.G., Rossi C., Boarini C., Cafaro A., Barbanti-Brodano G., Ensoli B., and Caputo A. DNA Immunization with HIV-1 tat Mutated in the trans Activation Domain Induces Humoral and Cellular Immune Responses Against Wild-Type Tat. *J. Immunol.*, 162:5631-5638, 1999.

Cook P.M., Whitby D., Calabro M.L., Luppi M., Kakoola D.N., Hjalgrim H., Ariyoshi K., Ensoli B., Davison A.J., Schulz T.F and the International Collaborative Group (Burdyga G., Barozzi P., Mbidde E.K., Kellam P., Giannoudis A., Khoo S., Melbye M., Whittle H., Monini P., Buttò S., Hatzakis A., Newton R., Hadarson S., Dalberg J., Dictor M., Christofferson P., McGeoch D., and Weiss R.A.). Variability and evolution of Kaposi's sarcoma-associated herpesvirus in Europe and Africa. *AIDS*, 13:1165-1176, 1999.

Ensoli B. Control of SHIV-89.6P Infection of Cynomolgus Monkeys by an HIV-1 Tat Vaccine. *AIDS Res. Hum. Retrov.*, Conference Summary: "Targeting HIV Reservoirs and Reconstituting the Immune System", Washington, April 18-19, 1999, pp. 1615-1616.

Ensoli B. Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 Tat vaccine. *Cent Gardes Book, Douzième Colloques de Cent Gardes*, Editions Elsevier, pp 77-82, 1999.

Ensoli B., and Stürzl M. HHV-8 and multistep tumorigenesis. *Trends in Microbiology (Letters)*, 7:310-311, 1999.

Ensoli B., Monini P., and Sgadari C. Pathogenesis and cell biology of Kaposi's sarcoma. *HIV and the New Viruses Second Edition*. Eds. Prof. A. Dalglish and Prof. R. Weiss, Chapter 19, 385-413, 1999.

Fiorelli V., Barillari G., Toschi E., Sgadari C., Monini P., Stürzl M., and Ensoli B. IFN- γ induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis. *J. Immunol.*, 162:1165-1170, 1999.

Goletti D., Macchia I., Pace M., Leone P., Sernicola L., Maggiorella M.T., Cafaro A., Baroncelli S., Verani P., Ensoli B. and Titti F. Inhibition of SHIV replication by CD8⁺ T lymphocytes from macaques immunized with live attenuated SIV. In Monduzzi Eds. *International Proceedings Division Fourth European Conference on Experimental AIDS Research*, Tampere (Finland), June 18-21, 1999, pp. 85-89.

Federico M. Lentiviruses as gene delivery vectors. *Cur. Opin. Biotechnol.* 10:448-453, 1999.

Maggiorella M.T., Koanga-Mogtomo M.L., Sernicola L., Corrias F., Negri D.R.M., Cesolini A., Baroni C., Verani P., Titti F. SIV-infected non-human primates as an animal model to study the pathogenesis of lymphoproliferative disorders. *The Fourth European Conference on Experimental AIDS Research. ECEAR. Tampere (Finlandia) 18-21 June, 1999*, 101-104, Monduzzi Editore, 1999.

Maggiorella M.T., Sernicola L., Baroncelli S., Koanga-Mogtomo M.L., Macchia I., Michelini Z., Belli R., Iale E., Corrias F., Verani P., Titti F. Multiple exposures to SIV strains and to SHIV89.6P do not abrogate protection in cynomolgus monkeys vaccinated with a Δ -Nef live attenuated virus. *The Fourth European Conference on Experimental AIDS Research. ECEAR, Tampere (Finlandia) 18-21 June, 1999*, 105-110, Monduzzi Editore, 1999.

Mihalcea A.M., Smith D.L., Monini P., Sgadari C., Ensoli B., and Gill P.S. Treatment update for AIDS-related Kaposi's sarcoma. *AIDS* 13:S215-S225, 1999.

Monini P., Carlini F., Franco M., and Ensoli B. Retrovirus ed herpesvirus nella patogenesi del sarcoma di Kaposi. *GIMMOC* 3(2):135-150, 1999.

Monini P., Carlini F., Stürzl M., Rimessi P., Superti F., Franco M., Melucci-Vigo G., Cafaro A., Goletti D., Sgadari C., Buttò S., Leone P., Leone P., Chiozzini C., Barresi C., Tinari A., Bonaccorsi A., Capobianchi M.R., Giuliani M., Di Carlo A., Andreoni M., Rezza G., and Ensoli B. Alpha interferon inhibits Human Herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells. *J. Virol.*, 73:4029-4041, 1999.

Monini P., Colombini S., Stürzl M., Goletti D., Cafaro A., Sgadari C., Buttò S., Franco M., Leone P., Fais S., Leone P., Melucci-Vigo G., Chiozzini C., Carlini F., Ascherl G., Cornali E., Ziezt C., Ramazzotti E., Ensoli F., Andreoni M., Pezzotti P., Rezza G., Yarchoan R., Gallo R.C., and Ensoli B. Reactivation and Persistence of Human Herpesvirus-8 Infection in B Cells and Monocytes by Th-1 Cytokines Increased in Kaposi's Sarcoma. *Blood*, 93:4044-4058, 1999.

Pellett P.E., Spira T.J., Bagasra O., Boshoff C., Corey L., de Lellis L., Huang M.L., Lin J.C., Matthews S., Monini P., Rimessi P., Sosa C., Wood C., Stewart J.A. Multicenter comparison of PCR assays for detection of human herpesvirus 8 DNA in semen. *J. Clin. Microbiol.*, 37:1298-30, 1999.

Rezza G., Andreoni M., Dorrucchi M., Pezzotti P., Monini P., Zerboni R., Salassa B., Colangeli V., Sarmati L., Nicastrì E., Barbanera M., Pristera R., Aiuti F., Ortona L., and Ensoli B. Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases. *J. Natl. Cancer Inst.*, 91:1468-1474, 1999.

Rezza G., Dorrucchi M., Andreoni M., Arpino C., De Luca A., Monini P., Nicastrì E., Alliegro M.B., Pezzotti P., and Ensoli B. for the Italian HIV-Seroconversion Study (Sinicco A., Angarano G., Tarantini G., Lazzarin A., Salassa B., Pristerà R., Tirelli U., Mazzarello G., Colangeli V., Castelli F., Alberici F., Ursitti M.A., Barbanera M., Zaccarelli M., Ortona L., and Aiuti F.). Does HHV-8 have a protective role on the development of HIV encephalopathy?. *Neurology*, 53:2032-2036, 1999.

Sernicola L., Corrias F, Koanga-Mogtomo M.L., Baroncelli S., Di Fabio S., Maggiorella M.T., Belli R., Michelini Z., Macchia I., Cesolini A., Cioè L., Verani P., Titti F. Long-lasting protection by live attenuated simian immunodeficiency virus in cynomolgus monkeys: no detection of reactivation after stimulation with a recall antigen. *Virology*, 256:291-302, 1999.

Sirianni M.C., Vincenzi L., Topino S., and Ensoli B. Human beta chemokines and Kaposi's sarcoma. *The FASEB Journal*, 13. N. 5, 1999.

Sirianni M.C., Vincenzi L., Topino S., Mezzaroma I., Pinter E., Barbone B., Monini P., and Ensoli B. Type 1 and type 2 cytokine profile in AIDS-Kaposi's sarcoma patients after highly active antiretroviral therapy. In Monduzzi Eds., Fourth European Conference on Experimental AIDS Research (ECEAR), Tampere, Finland, June 18-21, 1999.

Stürzl M., and Ensoli B. Big but weak: how many pathogenic genes does human herpesvirus-8 need to cause Kaposi's sarcoma? *Int. J. Oncol.*, 14:287-289, 1999.

Stürzl M., Ascherl G., Di Bartolo C., Tschachler E., Monini P., Ensoli B., and Hohenadl C. Angiogene Wachstumsfaktoren und humanes Herpesvirus-8: Schlüsselregulatoren der AIDS-assoziierten Vaskulopathie. In: HIV-Infekt. Brockmeyer, Brodt, Hoffman, Reimann, Stücker, Altmeyer (Eds.) Springer Verlag Berlin, Heidelberg, New York, pp. 88-94, 1999.

Stürzl M., Hohenadl C., Zietz C., Castanos-Velez E., Wunderlich A., Ascherl G., Biberfeld P., Monini P., Browning P.J., and Ensoli B. Expression of the K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells. *J. Natl. Cancer Inst.*, 91:1725-1733, 1999.

Stürzl M., Wunderlich A., Ascherl G., Hohenadl C., Monini P., Zietz C., Browning P.J., Neipel F., Biberfeld P., and Ensoli B. Human herpesvirus-8 (HHV-8) gene expression in Kaposi's sarcoma (KS) primary lesions: an in situ hybridization study. *Leukemia*, 13:S110-S112, 1999.

2000

Alessandrini L., Santarcangelo A.C., Olivetta E., Ferrantelli F., D'Aloja P., Pugliese K., Pelosi E., Chelucci C., Mattia G., Peschle C., Verani P. and Federico M. T-tropic human immunodeficiency virus (HIV) type 1 Nef protein enters human monocyte-macrophages and induces resistance to HIV replication: a possible mechanism of HIV T-tropic emergence in AIDS. *J. Gen. Virol.*, 1:2905-2917, 2000.

Annunziato F., Galli G., Nappi F., Cosmi L., Manetti R., Maggi E., Ensoli B., and Romagnani S. Limited expression of R5-tropic HIV-1 in CCR-5 positive type 1-polarized T cells explained by their ability to reproduce RANTES, MIP-1 α and MIP-1 β . *Blood*, 95:1167-1174, 2000.

Borsetti A., Parolin C., Ridolfi B., Sernicola L., Geraci A., Ensoli B., and Titti F. CD4-independent infection of two CD4-/CCR5-/CXCR4+ pre-T-cell lines by human and simian immunodeficiency viruses. *J. Virol.*, 74:6689-6894, 2000.

Cafaro A., Caputo A., Maggiorella M.T., Baroncelli S., Fracasso C., Pace M., Borsetti A., Sernicola L., Negri D.R.M., Ten Haaf P., Betti M., Michelini Z., Macchia I., Fanales-Belasio E., Belli R., Corrias F., Buttò S., Verani P., Titti F., and Ensoli B. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. *J. Med. Primatol.*, 29: 193-208, 2000.

Carbone A., Gloghini A., Bontempo D., Monini P., Tirelli U., Volpe R., Browning PJ., Gaidano GL. Proliferation in HHV-8-positive primary effusion lymphomas is associated with expression of HHV-8 cyclin but independent of p27^{kip1}. *Am. J. Pathol.*, 156:1209-1215, 2000.

Carbone A., Gloghini A., Cozzi M.R., Capello D., Steffan A., Monini P., De Marco L., Gaidano G.L. Expression of MUM1/IRF4 selectively clusters with primary effusion lymphoma among lymphomatous effusions: implications for disease histogenesis and pathogenesis. *Br. J. Haematol.*, 111:247-257, 2000.

Clerici M., Buttò S., Lukwiya M., Saresella M., Declich S., Trabattoni D., Pastori C., Piconi S., Fracasso C., Fabiani M., Ferrante P., Rizzardini G., and Lopalco L. for the Italian-Ugandan AIDS Project (Accorsi S., Amet O.A., Arienti D., Awil P.O., Barassi C., Benon B., Biasin M., Cogliati M., Colombo F., Corti P., Cristofaro A., Ensoli B., Fossati S., Fusi M.L., Greco D., Jacob O., Milazzo F., Ranghiasi A., Rosolen T., Villa M.L., Tancredi P., Zagliani A.). Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. *AIDS*, 14:2083-2092, 2000.

Conti L., Varano B., Gauzzi M.C., Matarresse P., Federico M., Malorni W., Belardelli F. and Gessani S. Impairment of Human Immunodeficiency Virus Type I entry into T Cells by constitutive expression of the HIV-1 Vpr protein: role of CD4 down-modulation. *J. Virol.* 74:10207-10211, 2000.

Di Fabio S., Trabattoni D., Geraci A., Ruzzante S., Panzini G., Fusi M.L., Chiarotti F., Corrias F., Belli R., Verani P., Dalglish A., Clerici M., Titti F. Study of immunological and virological parameters during thalidomide treatment of SIV-infected cynomolgus monkeys. *J. Med. Primatol.* 29:1-10, 2000.

Ensoli B., and Buttò S. The development of a vaccine against AIDS based on the HIV-1 Tat protein. *South African J. of Science* 96:324-327, 2000.

Ensoli B., and Cafaro A. Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine. *J. Biol. Regul. and Homeost. Agents*, 14:22-26, 2000.

Ensoli B., Monini P., and Sgadari C. Pathogenesis of Kaposi's sarcoma (KS): new insights in KS treatment. In: *Anlaids Notizie (Speciale)*, Anno 10, Supplemento al n. 6, Dicembre 2000, pp. 28-38.

Ensoli B., Nappi F., and Buttò S. Meccanismo di infezione dei virus dell'immunodeficienza acquisita (HIV-1, HIV-2, SIV). *Enciclopedia Medica Italiana "Retrovirus"*, Aggiornamento II, Tomo III, pp. 5085-5089, 2000.

Ensoli B., Stürzl M., and Monini P. Cytochine-mediated growth promotion of Kaposi's sarcoma and primary effusion lymphoma. *Sem. Cancer Biol.*, 10:367-381, 2000.

Olivetta, K. Pugliese, R. Bona, P. d'Aloja, F. Ferrantelli, A.C. Santarcangelo, G. Mattia, P. Verani, and M. Federico. cis Expression of the F12 Human Immunodeficiency Virus (HIV) Nef allele transforms the highly productive NL4-3 HIV type 1 to a replication defective strain: involvement of both Env gp41 and CD4 intracytoplasmic tails. *J. Virol.* 71:483-492, 2000.

Pintèr C., Beltrami S., Stoiber H., Negri D.R.M., Titti F., Clivio A. Interference with complement regulatory molecules as a possible therapeutic strategy in HIV infection. *Exp. Opin. Investig. Drugs*, 9:199-205, 2000.

Rezza G., Befeuka Tchangmena O., Andreoni M., Bugarini R., Toma L., Kaou Bakary D., Glikoutou M., Sarmati L., Monini P., Pezzotti P., and Ensoli B. Prevalence and risk factors for Human Herpesvirus 8 infection in Northern Cameroon. *Sexually Transmitted Diseases*, 27:159-164, 2000.

Rezza G., Dorrucchi M., Serraino D., Andreoni M., Giuliani M., Zerboni R., Sarmati L., Colangeli V., Salassa B., Monini P., Ensoli B., and Pezzotti P. for the Italian Seroconversion Study. Incidence of Kaposi's sarcoma and HHV-8 seroprevalence among homosexual men with known dates of HIV seroconversion. *AIDS*, 14:1647-1653, 2000.

Ridolfi B., Parolin C., Sernicola L., Fulgenzi D., Geraci A., Ensoli B., Titti F., and Borsetti A. Susceptibility of two CD4- T cell lines to HIV and SIV infection. *The Fifth European Conference on Experimental AIDS Research (ECEAR)*, Madrid (Spain), June 16-19, pp. 113-119, 2000.

Sgadari C., Toschi E., Palladino C., Barillari G., Carlei D., Cereseto A., Ciccolella C., Yarchoan R., Monini P., Stürzl M., and Ensoli B. Mechanism of Paclitaxel activity in Kaposi's sarcoma. *J. Immunol.* 165:509-517, 2000.

Tinari A., Monini P., Marchetti M., Ammendolia M.G., Leone P., Ensoli B., and Superti F. Lytic growth of human herpesvirus 8: morphological aspects. *Ultrastructural Pathol.*, 24:301-310, 2000.

2001

Accorsi S., Fabiani M., Lukwija M., Onek P.A., Di Mattei P., Declich S. for the Italian-Ugandan AIDS Cooperation Program (Greco D., Dente M.G., Tancredi P., Ranghiasi A., Corti P., Corrado B., Onyut A., Ouma J., Hasman A., Biryahwabo B., Rosolen T., Ensoli B., Buttò S., Clerici M., Zagliani A., Rizzardini G., Milazzo F., Piconi S., Ferrante P., Saresella M., Aloï A., Cosulich A). The increasing burden of infectious diseases on hospital services at St. Mary's Hospital Lacor, Gulu, Uganda. *Am. J. Trop. Med. Hyg.*, 64:154-158, 2001.

Andreoni M., Goletti D., Pezzotti P., Pozzetto A., Monini P., Sarmati L., Farchi F., Tisone G., Piazza A., Pisani F., Angelico M., Leone P., Citterio F., Ensoli B., Rezza G. Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi's Sarcoma in renal and liver transplant recipients. *J. Infect.*, 43:195-199, 2001.

Ascherl G., Sgadari C., Bugarini R., Bogner J., Schatz O., Ensoli B., and Stürzl M. Serum concentrations of fibroblast growth factor-2 are increased in HIV type 1-infected patients and inversely related with survival probability. *AIDS Res. Hum. Retrov.*, 17:1035-1039, 2001.

Barillari G., Albonici L., Incerpi F., Bogetto L., Pistrutto G., Volpi A., Ensoli B., and Manzari V. Inflammatory cytokines stimulate vascular smooth muscle cells locomotion and growth by enhancing $\alpha 5\beta 1$ integrin expression and function. *Atherosclerosis*, 154:377-385, 2001.

Betti M., Voltan R., Marchisio M., Mantovani I., Boarini C., Nappi F., Ensoli B., and Caputo A. Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application. *Vaccine*, 19:3408-3419, 2001.

Bussolino F., Mitola S., Serini G., Barillari G., and Ensoli B. Interactions between endothelial cells and HIV-1. *Int. J. Biochem. Cell Biol.*, 33:371-390, 2001.

Buttò S. Vaccino: una luce in fondo al tunnel?. *Positifs*, 43:14-19, 2001.

Buttò S., Tripiciano A. and Scoglio A. Il corso dell'infezione da virus dell'immunodeficienza umana. "Positifs" 47 (supplement: Infezione da HIV – Repertorio delle sperimentazioni terapeutiche, 2001): 10-14, 2001.

Cafaro A., Titti F., Fracasso C., Maggiorella M.T., Baroncelli S., Caputo A., Goletti D., Borsetti A., Pace M., Fanales-Belasio E., Ridolfi B., Negri D.R.M., Sernicola L., Belli R., Corrias F., Macchia I., Leone P., Michelini Z., ten Haaf P., Buttò S., Verani P., and Ensoli B. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). *Vaccine*, 19:2862-2877, 2001.

D'Aloja P., Santarcangelo A.C., Arold S., Baur A., and Federico M. Genetic and functional analysis of the human immunodeficiency virus (HIV) type1-inhibiting F12-HIVnef allele. *J. Gen. Virol.*, 82:2735-2745, 2001.

De Maria A., Biassoni R., Fogli M., Rizzi M., Cantoni C., Costa P., Conte R., Mavilio D., Ensoli B., Cafaro A., Moretta A., Moretta L. Identification, molecular cloning and functional characterization of NKp46 and NKp30 natural cytotoxicity receptors in *Macaca Fascicularis* NK cells. *Eur. J. Immunol.*, 31:3546-3556, 2001.

Ensoli B., and Cafaro A. Novel strategies toward the development of an effective vaccine to prevent Human Immunodeficiency Virus infection or Acquired Immunodeficiency Virus. In: *AIDS Clinical Review 2000/2001*, Volberding and Jacobson Eds., pp. 23-61.

Ensoli B., Sgadari C., Barillari G., Sirianni M.C., Stürzl M., and Monini P. Biology of Kaposi's Sarcoma. *Eur. J. Cancer*, 37:1251-1269, 2001.

Ensoli B., Stürzl M., and Monini P. Reactivation and role of HHV-8 in Kaposi's sarcoma initiation. *Adv. Cancer Res.*, 81:161-200, 2001.

Fackler O.T., D'Aloja P., Baur A.S., Federico M., and Peterlin B.M. Nef from Human Immunodeficiency Virus Type 1F12 Inhibits viral production and infectivity. *J. Virol.*, 75:6601-6608, 2001.

Fackler O.T., Wolf D., Weber H.O., Laffert B., D'Aloja P., Schuler-Thurner B., Geffin R., Saksela K., Geyer M., Peterlin B.M., Schuler G., Baur A.S. A natural variability in the proline-rich motif of Nef modulates HIV-1 replication in primary T cells. *Curr Biol.*, 11:1294-1299, 2001.

Federico M., Percario Z., Olivetta E., Fiorucci G., Muratori C., Micheli A., Romeo G., and Affabris E. Human Immunodeficiency virus type 1 Nef activates STAT1 in human monocytes/macrophages through the release of soluble factors. *Blood*, 98:2752-2761, 2001.

Guenzi E., Töpolt K., Cornali E., Lubeseder-Martellato C., Zietz C., Kremmer E., Nappi F., Schwemmler M., Hohenadl C., Jörg A., Matzen K., Barillari G., Tschachler E., Monini P., Ensoli B., and Stürzl M. The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. *EMBO J.*, 20:5568-5577, 2001.

Laus M., Sparnacci K., Ensoli B., Buttò S., Caputo A., Mantovani I., Zuccheri G., Samori B., and Tondelli L. Complex associates of plasmid DNA and a novel class of block Copolymers with PEG and cationic segments as new vectors for gene delivery. *J. Biomater. Sci. Polym. Ed.*, 12:209-228, 2001.

Monini P., Sirianni M.C., Franco M., Vincenzi L., Topino S., Goletti D., Leone P., Leone P., Chiozzini C., Nicastrì E., Andreoni M., Borduagni O., Sgadari C., Rezza G., Stürzl M., and Ensoli B. Clearance of human herpesvirus 8 from blood and regression of leukopenia-associated aggressive classic Kaposi's sarcoma during interferon-alpha therapy: a case report. *Clin. Infect. Dis.*, 33:1782-1785, 2001.

Negri D, Baroncelli S, Michelini Z, Macchia I, Belli R, Catone S, Incitti F, ten Haaf P, Corrias F, Cranage MP, Polyanskaya N, Norley S, Heeney J, Verani P, Titti F. Effect of vaccination with recombinant modified vaccinia virus Ankara expressing structural and regulatory genes of SIVmacJ5 on the kinetics of SIV replication in cynomolgus monkeys. *J. Med. Primatol.*, 30:197-206, 2001.

Rezza G., Danaya R.T., Wagner T.M., Sarmati L., Owen I.L., Monini P., Andreoni M., Suligoï B.S., Ensoli B., and Pozio E. Human Herpesvirus-8 and Other Viral Infections, Papua New Guinea. *Emerg. Infect. Dis.*, 7:893-895, 2001.

Rimessi P., Bonaccorsi A., Stürzl M., Fabris M., Brocca-Cofano E., Caputo A., Melucci-Vigo G., Falchi M., Cafaro A., Cassai E., Ensoli B., and Monini P. Transcription pattern of human

herpesvirus 8 open reading frame K3 in primary effusion lymphoma and Kaposi's sarcoma. *J. Virol.*, 75:7161-7174, 2001.

Schatz O., Monini P., Bugarini R., Neipel F., Schulz T.F., Andreoni M., Erb P., Eggers M., Haas J., Buttò S., Lukwiya M., Bogner J.R., Yaguboglu S., Sheldon J., Sarmati L., Goebel F. D., Hintermaier R., Enders G., Regamey N., Wernli M., Stürzl M., Rezza G., and Ensoli B. Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda: multicentre study with multiple and novel assays. *J. Med. Virol.*, 65:123-132, 2001.

Serraino D., Toma L., Andreoni M., Buttò S., Tchangmena O., Sarmati L., Monini P., Franceschi S., Ensoli B., and Rezza G. A seroprevalence study of human herpesvirus type 8 (HHV8) in eastern and Central Africa and in the Mediterranean area. *Eur. J. Epidemiol.*, 17:871-876, 2001.

Sirianni M.C., Libi F., Scaramuzzi D., Topino S., Campagna M., Colbacchi B., Novi A., De Cristofaro M.R., Fiorelli V., Ensoli F., and Ensoli B. Modulation of the natural killer cell activity of peripheral blood mononuclear cells by the HIV Tat protein. Proceedings of the 6th European Conference on Experimental AIDS Research (ECEAR 2001), Edinburgh (Scotland), June 23-26, 2001, pp.81-85.

Stürzl M., Zietz C., Monini P., and Ensoli B. Human herpesvirus-8 and Kaposi's sarcoma: relationship with the multi-step concept of tumorigenesis. *Adv. Cancer Res.*, 81:125-159, 2001.

Ten Haaft P., Almond N., Biberfeld G., Cafaro A., Cranage M., Ensoli B., Hunsmann G., Polyanskaya N., Stahl-Hennig C., Thortensson R., Titti F., Heeney J. Comparison of early plasma rna loads in different macaque species and the impact of different routes of exposure on siv/shiv infection. *J. Med. Primatol.*, 30:207-214, 2001.

Tondelli L., Canto E., Pistagna A., Buttò S., Tripiciano A., Cortesi R., Sparnacci K. And Laus M. Tailor-made core-shell nanospheres for antisense oligonucleotide delivery: IV. Adsorption/release behaviour. *J. Biomater. Sci. Polymer Ed.*, 12: 1281-1372, 2001.

Toschi E., Barillari G., Sgadari C., Bacigalupo I., Cereseto A., Carlei D., Palladino C., Zietz C., Leone P., Stürzl M., Buttò S., Cafaro A., Monini P., and Ensoli B. Activation of Matrix-Metalloproteinase-2 and Membrane-Type-1-Matrix-Metalloproteinase in Endothelial Cells and Induction of Vascular Permeability in vivo by the Human Immunodeficiency Virus-1 Tat protein and Basic Fibroblast Growth Factor. *Mol. Biol. Cell*, 12:2934-2946, 2001.

Wolf D., Witte V., Laffert B., Blume K., Stromer E., Trapp S., D'Aloja P., Schürmann A., Baur AS. HIV-1 Nef associated PAK and PI3-kinases stimulate Akt-independent Bad-phosphorylation to induce anti-apoptotic signals. *Nat Med.*, 7:1217-1224, 2001.

2002

Almond N., Anzala O., Bektimirov T., Berman P., Birx D., Carneiro J., Chongprasert S., Cichutek K., Darbyshire J., Duarte C., Ensoli B., Fenyo E.M., Girard M., Goldenthal K., Golding H., Holmes H., Johnston M., Mallet L., Mawle A., Mugerwa R., Pitisuttithum P., Rees H., Robertson J., Rowland-Jones S., Sang G., Schild G., Shao Y., Sheets R., Takemori T., Tramont E., Vandepapeliere P., van der Groen G., Weiner D., and Widdus R. Scientific considerations for the regulation and clinical evaluation of HIV/AIDS preventive vaccines. (Collective views of an international group of experts, Report from a WHO-UNAIDS Consultation, Geneva, Switzerland, March 13-15, 2001); *AIDS*, 16:W15-W25, 2002.

Barillari G., and Ensoli B. Angiogenic Effects of Extracellular Human Immunodeficiency virus type 1 Tat Protein and its role in the pathogenesis of AIDS-associated Kaposi's Sarcoma. *Clin. Microbiol. Rev.*, 15:310-32, 2002.

Battistini A., Marsili G., Sgarbanti M., Ensoli B., and Hiscott J. Review: IRF Regulation of HIV-1 Long Terminal Repeat Activity. *J. Interferon Cytokine Res.* 22:27-37, 2002.

Broccolo F., Locatelli G., Sarmati L., Piergiovanni S., Veglia F., Andreoni M., Buttò S., Ensoli B., Lusso P., Malnati M.S. Calibrated Real-Time PCR Assay for Quantitation of Human Herpesvirus 8 DNA in Biological Fluids. *J. Clin. Microbiol.* 40:4652-4658, 2002.

Caputo A., Betti M., Altavilla G., Bonaccorsi A., Boarini C., Marchisio M., Buttò S., Sparnacci K., Laus M., Tondelli L., and Ensoli B. Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application. *Vaccine*, 20:2303-2317, 2002.

Cara A., Cafaro A., Baroncelli S., Maggiorella M.T., Negri D.R.M., Fanales-Belasio E., Moretti S., Michelini Z., Fiorelli V., Buttò S., Tripiciano A., Sernicola L., Scoglio A., Borsetti A., Ridolfi B., Macchia I., Mancini M.G., Belli R., Farcomeni S., Nappi F., Vardas E., Colvin M., Laguardia E., Caputo A., Magnani M., Titti F., and Ensoli B. Development of HIV/AIDS vaccine based on Tat: preclinical and clinical studies. In Monduzzi Eds., *International Proceedings Division, XIV International AIDS Conference, Barcelona (Spain), July 7 – July 12, 2002*, pp. 251-256.

Ensoli B. Gli inibitori delle proteasi di HIV hanno una potente azione anti-angiogenica ed anti-tumorale indipendente dalla loro attività anti-retrovirale. In: *Indinavir nella strategia terapeutica della malattia da HIV*, Edizioni Internazionali srl, Divisione EDIMES-Edizioni Medico-Scientifiche 2002, pp.59-78.

Ensoli B. HIV protease inhibitors have specific anti-cancer effects. *Biomed. & Pharmacother.*, Vol. 56, No. 8, 2002.

Ensoli B., and Cafaro A. HIV-1 Tat vaccines. *Virus Res.*, 82(1-2):91-101, 2002.

Fanales-Belasio E., Cafaro A., Cara A., Negri D.R.M., Fiorelli V., Buttò S., Moretti S., Maggiorella M.T., Baroncelli S., Michelini Z., Tripiciano A., Sernicola L., Scoglio A., Borsetti A., Ridolfi B., Bona R., ten Haaf P., Macchia I., Leone P., Pavone-Cossut M.R., Nappi F., Vardas E., Magnani M., Laguardia E., Caputo A., Titti F., and Ensoli B. HIV-1 Tat-Based Vaccines: from Basic Science to Clinical Trials. *DNA and Cell Biol.*, 21:599-610, 2002.

- Fanales-Belasio E., Moretti S., Nappi F., Barillari G., Micheletti F., Cafaro A., and Ensoli B. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function and antigen-specific T cell responses. *J. Immunol.*, 168:197-206, 2002.
- Giuliani M., Mastroianni A., Di Carlo A., Donati P., Miceli M., Monini P., Rezza G. Onset of non-AIDS Kaposi's sarcoma during therapy with interferon alfa-2a in an 82-year-old man with concomitant cutaneous T-cell lymphoma. *Arch. Dermatol.*, 138:533-537, 2002.
- Lubeseder-Martellato C., Guenzi E., Jörg A., Töpolt K., Naschberger E., Kremmer E., Zietz C., Tschachler E., Hutzler P., Schwemmle M., Matzen K., Grimm T., Ensoli B., and Stürzl M. Guanylate-binding protein-1 expression is selectively induced by inflammatory cytokines and is an activation marker of endothelial cells during inflammatory diseases. *Am. J. Pathol.*, 161:1749-1759, 2002.
- Malnati M., Broccolo F., Nozza S., Sarmati L., Ghezzi S., Locatelli G., Delfanti F., Capiluppi B., Careddu A., Andreoni M., Monini P., Poli G., Lazzarin A., Lusso P., and Tambussi G. Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy. *Blood*, 100:1575-1578, 2002.
- Micheletti F., Monini P., Fortini C., Rimessi P., Bazzaro M, Andreoni M., Giuliani M., Traniello S., Ensoli B., and Gavioli R. Identification of cytotoxic T lymphocyte epitopes of human herpes virus 8. *Immunology*, 106:395-403, 2002.
- Monini P., Sirianni M.C., and Ensoli B. Concomitant clearance of human herpesvirus 8 from blood and regression of leukopenia-associated aggressive classic Kaposi's sarcoma upon α -interferon therapy. *Oncol. Rev. J.*, issue 4, pp.18-20, 2002.
- Muratori C., Schiavoni I., Melucci-Vigo G., Olivetta E., Santarcangelo A.C., Pugliese K., Verani P., and Federico M. Inducible expression of the deltaNGFr/F12Nef fusion protein as a new tool for anti-HIV-1 gene therapy. *Hum. Gene Ther.*, 13:1751-1766, 2002.
- Rharbaoui F., Drabner B., Borsutzky S., Winckler U., Morr M., Ensoli B., Mühlradt P.F., and Guzman C.A. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. *Eur. J. Immunol.*, 32:2857-2865, 2002.
- Sgadari C., Barillari G., Toschi E., Carlei D., Bacigalupo I., Baccarini S., Palladino C., Leone P., Bugarini R., Malavasi L., Cafaro A., Falchi M., Valdembri D., Rezza G., Bussolino F., Monini P., and Ensoli B. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi's sarcoma. *Nat. Med.*, 8:225-232, 2002.
- Sgadari C., Monini P., Toschi E., Baccarini S., Grosso M.G., Moracci G., Malavasi L., and Ensoli B. HIV Protease Inhibitors inhibit Kaposi's sarcoma by blocking angiogenesis and tumour cell invasion. *Haematologica*, (Meeting Supplement 1 to n. 11) 87:37-41, 2002.
- Sgarbanti M., Borsetti A., Moscufo N., Bellocchi M.C., Ridolfi B., Nappi F., Marsili G., Marziali G., Coccia E.M., Ensoli B., and Battistini A. Modulation of HIV-1 Replication by Interferon Regulatory Factors. *J. Exp. Med.*, 195:1359-1370, 2002.
- Sirianni M.C., Libi F., Scaramuzzi D., Campagna M., Monini P., and Ensoli B. NK cell activity, HHV-8 infection and HAART. In Monduzzi Eds., *International Proceedings Division, XIV International AIDS Conference, Barcelona (Spain), July 7 – July 12, 2002*, pp. 39-41.

Sirianni M.C., Vincenti L., Topino S., Giovanetti A., Mazzetta F., Libi F., Scaramuzzi D., Andreoni M., Pinter E., Baccarini S., Rezza R., Monini P., and Ensoli B. NK cell activity controls human herpesvirus 8 latent infection and is restored upon HAART in AIDS patients with regressing Kaposi's sarcoma. *Eur. J. Immunol.*, 32:2711-2720, 2002.

Titti F., Zamarchi R., Maggiorella M.T., Sernicola L., Geraci A., Negri D., Borsetti A., Menin C., D'Andrea E., Modesti A., Masuelli L., Verani P., Chieco-Bianchi L., and Amadori A. Infection of simian B lymphoblastoid cells with simian immunodeficiency virus is associated with up-regulation of CD23 and CD40 cell surface markers. *J. Med. Virol.*, 68:129-140, 2002.

Toschi E., Sgadari C., Monini P., Barillari G., Bacigalupo I., Palladino C., Baccarini S., Carlei D., Grosso G., Sirianni M.C. and Ensoli B. Treatment of Kaposi's Sarcoma, an update. *Anti-Cancer Drugs*, 13:977-987, 2002.

Zamarchi R., Allavena P., Borsetti A., Stievano L., Tosello V., Marcato N., Esposito G., Roni V., Paganini C., Bianchi G., Titti F., Verani P., Gerosa G., Amadori A. Expression and functional activity of CXCR-4 and CCR-5 chemokine receptors in human thymocytes. *Clin. Exp. Immunol.*, 127: 321-330 2002.

2003

Alessandri G., Fiorentini S., Licenziati S., Bonafede M., Monini P., Ensoli B., and Caruso A. CD8(+)CD28(-) T lymphocytes from HIV-1-infected patients secrete factors that induce endothelial cell proliferation and acquisition of Kaposi's sarcoma cell features. *J. Interferon Cytokine Res.*, 23:523-531, 2003.

Barillari G., Sgadari C., Toschi E., Monini P., and Ensoli B. HIV protease inhibitors as new treatment options for Kaposi's sarcoma. *Drug Res. Update*, 6:173-181, 2003.

Borsutzky S., Fiorelli V., Ebensen T., Tripiciano A., Rharbaoui F., Scoglio A., Link C., Nappi F., Morr M., Buttò S., Cafaro A., Mühlradt P.F., Ensoli B., and Guzman CA. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant. *Eur. J. Immunol.*, 33:1548-1556, 2003.

Buttò S., Fiorelli V., Tripiciano A., Ruiz-Alvarez M.J., Scoglio A., Ensoli F., Ciccozzi M., Collacchi B., Sabbatucci M., Cafaro A., Guzmán C.A., Borsetti A., Caputo A., Vardas E., Colvin M., Lukwya M., Rezza G., Ensoli B., and the Tat Multicentric Study Group. Sequence conservation and antibody cross-recognition of the clade B human immunodeficiency virus (HIV) type 1 Tat Protein in HIV-1-Infected Italian, Ugandan and South Africans. *J. Infect. Dis.*, 188:1171-1180, 2003.

Buttò S., Tripiciano A., Scoglio A., Ruiz-Alvarez M.J., Rovetto C., and Salvi E. Diagnosi di infezione da HIV: test di laboratorio. *Positifs*, 54-55:35-37, 2003.

Caputo A., Gavioli R., Altavilla G., Brocca Cofano E., Boarini C., Betti M., Castaldello A., Lorenzini F., Micheletti F., Cafaro A., Sparnacci K., Laus M., Tondelli L., and Ensoli B. Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat. *Vaccine*, 21: 1103-1111, 2003.

Dominici S., Laguardia M.E., Serafini G., Chiarantini L., Fortini C., Tripiciano A., Brocca-Cofano E., Scoglio A., Caputo A., Fiorelli V., Gavioli R., Cafaro A., Ensoli B., and Magnani M. Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL. *Vaccine*, 21:2082-2090, 2003.

Ensoli B., Sgadari C., Barillari G., and Monini P. The Fibroblast Growth Factors. In: *The Cytokine Handbook* (IV Edition, Chapter 31, Thomson A. and Lotze M. Eds.), Vol. II, pp.747-781, 2003.

Grosso G., Sgadari C., Barillari G., Toschi E., Bacigalupo I., Carlei D., Palladino C., Baccarini S., Malavasi L., Moracci G., Leone P., Chiozzini C., Monini P., and Ensoli B. Trattamento del Sarcoma di Kaposi mediante gli inibitori della proteasi di HIV. *Recenti Progressi in Medicina* (Italian), Vol. 94, n. 2, pp.69-74, 2003.

Federico M. From lentiviruses to lentivirus vectors "Lentivirus Gene Engineering Protocols", Editor M. Federico, Humana Press Inc., Totowa, NJ, 2003.

Marinaro M., Riccomi A., Rappuoli R., Pizza M., Fiorelli V., Tripiciano A., Cafaro A., Ensoli B., and De Magistris M.T. Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. *Vaccine*, 21(25-26)-3503-4094, 2003.

Marsili G., Borsetti A., Sgarbanti M., Remoli A.L., Ridolfi B., Stellacci E., Ensoli B., and Battistini A. On the role of interferon regulatory factors in HIV-1 replication. *Ann. NY Acad. Sci.*, 1010:29-42, 2003.

Monini P., Sgadari C., Barillari G. and Ensoli B. The HIV protease inhibitors: anti-retroviral agents with anti-inflammatory, anti-angiogenic and anti-tumor activity. *J. Antimicrobial Chemother.*, 51:207-211, 2003.

Olivetta E., Percario Z., Fiorucci G., Mattia G., Schiavoni I., Dennis C., Jager J., Harris M., Romeo G., Affabris E., and Federico M. HIV-1 Nef Induces the release of inflammatory factors from human monocyte/macrophages: involvement of Nef endocytotic signals and NF-kB activation. *J. Immunol.* 170:1716-1727, 2003.

Percario Z., Olivetta E., Fiorucci G., Mangino G., Peretti S., Romeo G., Affabris E., and Federico M. Human immunodeficiency type 1 (HIV-1) Nef activates STAT3 in primary human monocyte/macrophages through the release of soluble factors: involvement of Nef domains interacting with the cell endocytotic machinery. *J. Leuk. Biol.*, 74:8221-831, 2003.

Savarino A., Bensi T., Chiocchetti A., Bottarel F., Mesturini R., Ferrero E., Colosso L., Deraglio S., Ortolan E., Buttò S., Cafaro A., Katada T., Ensoli B., Malavasi F., and Dianzani U. Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120. *FASEB J.*, 17:461-463, 2003.

Sgadari C., Monini P., Barillari G. and Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. *Lancet Oncol.*, 4:537-547, 2003.

Tuosto L., Marinari B., Andreotti M., Federico M., and Piccolella E. Vav exchange factor counteracts the HIV-1 Nef mediated decrease of plasma membrane GM1 and NF-AT activity in T cells. *Eur. J. Immunol.*, 33: 2186-2196, 2003.

2004

Buttò S. La sperimentazione vaccinale nei paesi in via di sviluppo. *Rapporti Istisan, Istituto Superiore di Sanità*, n 06/29, 2004.

Caputo A., Brocca-Cofano E., Castaldello A., Altavilla G., De Michele R., Marchisio M., Gavioli R., Rolen U., Chiarantini L., Cerasi A., Dominici S., Magnani M., Cafaro A., Sparnacci K., Laus M., Tondelli L., and Ensoli B. Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application. *Vaccine*, 22:2910-24, 2004.

Caputo A., Gavioli R. and Ensoli B. Recent advances in the development of HIV-1 Tat-based vaccines. *Curr. HIV Res.*, 2:357-376, 2004.

Cara A., Maggiorella M.T., Bona R., Sernicola L., Baroncelli S., Negri D.R.M., Leone P., Fagrouch Z., Heeney J., Titti F., Cafaro A., and Ensoli B. Circular viral DNA detection and junction sequence analysis from PBMC of SHIV-infected cynomolgus monkeys with undetectable virus plasma RNA. *Virology*, 324:531-539, 2004.

Di Fabio S., Corrias F., Monardo F., and Titti F. Flow cytometry analysis of immune cell populations isolated from cervicovaginal secretions of cynomolgus monkeys. *J Immunol. Methods*, 284:7-14, 2004.

Federico M. Targeting the Nef induced increase of HIV infectivity. *Curr Drug Targets Immune Endocr. Metabol. Disord.* 4:321-326, 2004.

Ferrantelli F., Cafaro A., and Ensoli B. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. *Curr. Opin. Biotech.*, 15:543-56, 2004.

Ferrero E., Orciani M., Vacca P., Ortolan E., Crovella S., Titti F., Saccucci F., Malavasi F. Characterization and phylogenetic epitope mapping of CD38 ADPR cyclase in the cynomolgus macaque. *BMC Immunol.*, 5:21, 2004.

Franzese O., Comandini A., Adamo R., Sgadari C., Ensoli B., and Bonmassar E. HIV-Tat down-regulates telomerase activity in the nucleus of human CD4+ T cells. *Cell Death Differ.*, 11:782-784, 2004.

Galli M.C., Caré A., Cianfriglia M., Crescenzi M., Dogliotti E., Federico M., and Testa U. Linee Guida sulla sperimentazione clinica di fase I con medicinali sperimentali per la terapia genica somatica. *Notiziario ISS, Istituto Superiore di Sanità, Vol. 17*, pp. 15-27, Luglio-Agosto 2004.

Gavioli R., Gallerani E., Fortini C., Fabris M., Bottoni A., Canella A., Bonaccorsi A., Marastoni M., Micheletti F., Cafaro A., Rimessi P., Caputo A. and Ensoli B. HIV-1 Tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. *J. Immunol.*, 173:3838-3843, 2004.

Goletti D., Carrara S., Vincenti D., Giacomini E., Fattorini L., Garbuglia A.R., Capobianchi M.R., Alonzi T., Firmi G. M., Federico M., Poli G., and Coccia E.M. Inhibition of HIV-1 replication in monocyte-derived macrophages by *Mycobacterium tuberculosis*. *J. Infect. Dis.*, 189:624-633, 2004.

Leuchte N., Berry N., Köhler B., Almond N., LeGrand R., Thorstensson R., Titti F., and Sauermann U. MhcDRB-sequences from cynomolgus macaques (*Macaca fascicularis*) of different origin. *Tissue Antigens*, 63:529-537, 2004.

Maggiorella M.T., Baroncelli S., Michelini Z., Fanales-Belasio E., Moretti S., Sernicola L., Cara A., Negri D.R.M., Buttò S., Fiorelli V., Tripiciano A., Scoglio A., Caputo A., Borsetti A., Ridolfi B., Bona R., ten Haaft P., Macchia I., Leone P., Pavone-Cossut M.R., Nappi F., Ciccozzi M., Heeney J., Titti F., Cafaro A., and Ensoli B. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. *Vaccine*, 22:3258-3269, 2004.

Michelini Z., Negri D.R., Baroncelli S., Catone S., Comini A., Maggiorella M.T., Sernicola L., Crostarosa F., Belli R., Mancini M.G., Farcomeni S., Fagrouch Z., Ciccozzi M., Rovetto C., Liljestrom P., Norley S., Heeney J., Titti F. T-cell-mediated protective efficacy of a systemic vaccine approach in cynomolgus monkeys after SIV mucosal challenge. *J Med Primatol.*, 33:251-261, 2004.

Monini P., Sgadari C., Toschi E., Barillari G., and Ensoli B. Antitumor effects of antiretroviral activity. *Nat. Cancer Rev.*, 4:861-875, 2004.

Mooij P., Nieuwenhuis I.G., Knoop C.J., Doms R.W., Bogers W.M.J.M., Ten Haaft P.J.F., Niphuis H., Koornstra W., Bieler K., Koestler J., Morein B., Cafaro A., Ensoli B., Wagner R., and Heeney J.L. Qualitative T-Helper Responses to Multiple Viral Antigens Correlate with Vaccine-Induced Immunity to Simian/Human Immunodeficiency Virus Infection. *J. Virol.*, 78:3333-3342, 2004.

Negri D.R.M., Buffa V., Leone P., Bona R., Borghi M., Carlini F., De Angelis F., Indraccolo S., Ensoli B., Cara A. Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. *J. Immunol. Methods*, 291:153-163, 2004.

Negri D.R., Baroncelli S., Catone S., Comini A., Michelini Z., Maggiorella M.T., Sernicola L., Crostarosa F., Belli R., Mancini M.G., Farcomeni S., Fagrouch Z., Ciccozzi M., Boros S., Liljestrom P., Norley S., Heeney J., and Titti F. Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge. *J. Gen. Virol.* 85:1191-1201, 2004.

Pistello M., Del Santo B., Buttò S., Bargagna M., Domenici R., and Bendinelli M. Genetic and phylogenetic analyses of HIV-1 corroborate the transmission link hypothesis. *J. Clin. Virol.*, 30:11-18, 2004.

Ridolfi B., Titti F., Fulgenzi D., Maggiorella M.T., Tinari A., Superti F., Parolin C., Ensoli B., and Borsetti A. Infection of a Simian B Cell Line by Human and Simian Immunodeficiency Viruses. *AIDS Res. Hum. Retrov.*, 20:723-732, 2004.

Schiavoni I., Muratori C., Piacentini V., Giammarioli A.M., and Federico M. The HIV-1 Nef Protein: How An AIDS Pathogenetic Factor Turns to a Tool for Combating AIDS. *Current Drug Targets - Immune, Endocrine & Metabolic Disorders*, 4:19-27, 2004.

Schiavoni I., Trapp S., Santarcangelo A.C., Piacentini V., Pugliese K., Baur A., and Federico M. HIV-1 Nef enhances both membrane expression and virion incorporation of Env products. A model for the Nef-dependent increase of HIV-1 infectivity. *J Biol Chem.*, 279:22996-3006, 2004.

Sgarbanti M., Marsili G., Remoli A.L., Ridolfi B., Stellacci E., Borsetti A., Ensoli B., and Battistini A. Analysis of the signal transduction pathway leading to human immunodeficiency virus-1-induced interferon regulatory factor-1 upregulation. *Ann. NY Acad. Sci.*, 1030:187-195, 2004.

Sirianni M.C., Libi F., Campagna M., Scaramuzzi D., Monini P., and Ensoli B. Role of killer inhibitory receptors in human herpesvirus type 8 infection and KS development. In Monduzzi Eds., *International Proceedings Division, 12th International Congress of Immunology and 4th Annual Conference of FOCIS, Montreal (Canada), July 18 – July 23, 2004*, pp. 257-259.

Witte V., Laffert B., Rosorius O., Lischka P., Blume K., Galler G., Stilper A., Willbold D., D'Aloja P., Sixt M., Kolanus J., Ott M., Kolanus W., Schuler G., and Baur A.S. HIV-1 Nef mimics an integrin receptor signal that recruits the polycomb group protein Eed to the plasma membrane. *Mol. Cell.*, 13:179-190, 2004.

2005

Biassoni R., Fogli M., Cantoni C., Costa P., Conte R., Koopman G., Cafaro A., Ensoli B., Moretta A., Moretta L., De Maria A. Molecular and functional characterization of NKG2D, NKp80, and NKG2C triggering NK cell receptors in rhesus and cynomolgus macaques: monitoring of NK cell function during simian HIV infection. *J. Immunol.* 1:174:5695-5705, 2005.

Ensoli B. AIDS Vaccine Integrated Project (AVIP). *BIOforum Europe* (01/2005), pp 38-40, 2005.

Ensoli B. Criteria for selection of HIV vaccine candidates-general principles. *Microbes Infect.*, 7:1433-1435, 2005.

Ensoli B. Introduction: rational vaccine strategies against AIDS. *Microbes Infect.*, 7:1385, 2005.

Ensoli B. Rational vaccine strategies against AIDS: background and rationale. *Microbes Infect.*, 7:1445-1452, 2005.

Ensoli B., Buttò S., and Fiorelli V. Il vaccino contro l'HIV e l'AIDS. *Notiziario dell'Istituto Superiore di Sanità*, 18:9-13, 2005.

Ensoli B., Cafaro A., Caputo A., Fiorelli V., Ensoli F., Gavioli R., Ferrantelli F., Cara A., Titti F., and Magnani M. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env. *Microbes Infect.*, 7:1392-1399, 2005.

Ensoli F., Fiorelli V., Buttò S., Gavioli R., Caputo A., Monini P., Ferrantelli F., Titti F., Cafaro A., and Ensoli B. HIV/AIDS vaccine based on the native Tat protein: from basic science to clinical trials. *Giornale Italiano di Malattie Infettive (Italian)*, Vol.11(4):151-155, 2005.

Olivetta E., Pietraforte D., Schiavoni I., Minetti M., Federico M., and Sanchez M. HIV-1 Nef regulates the release of superoxide anion from human macrophages. *Biochem. J.*, 390:591-602, 2005.

Peretti S., Schiavoni I., Pugliese K., and Federico M. Cell Death Induced by the Herpes Simplex Virus-1 Thymidine Kinase Delivered by Human Immunodeficiency Virus-1-Based Virus-like Particles. *Mol. Ther.* 12:1185-1196, 2005.

Rezza G., Fiorelli V., Dorrucchi M., Ciccozzi M., Tripiciano A., Scoglio A., Collacchi B., Ruiz-Alvarez M., Giannetto C., Caputo A., Tomasoni L., Castelli F., Sciandra M., Sinicco A., Ensoli F., Buttò S., and Ensoli B. The Presence of Anti-Tat Antibodies Is Predictive of Long-Term Non-Progression to AIDS or Severe Immunodeficiency: Findings from a Cohort of HIV Seroconverters. *J. Infect. Dis.*, 191:1321-1324, 2005.

Sirianni M.C., Libi F., Campagna M., Rossi D., Capello D., Sciaranghella G., Carbone A., Simonelli C., Monini P., Gaidano G., and Ensoli B. Down-regulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development. *Br. J. Haematol.*, 130:92-95, 2005.

Sparnacci K., Laus M., Tondelli L., Bernardi C., Magnani L., Corticelli F., Marchisio M., Ensoli B., Castaldello A., and Caputo A. Core-shell microspheres by dispersion polymerization as promising delivery systems for proteins. *J. Biomater. Sci. Polymer. Edn*, 16:1557-1574, 2005.

Vallanti G., Lupo R., Federico M., Mavilio F., and Bovolenta C. T Lymphocytes transduced with a lentiviral vector expressing F12-Vif are protected from HIV-1 infection in an APOBEC3G-independent manner. *Mol Ther.*, 12:697-706, 2005.

Vardas E., Buttò S., Glashoff R., Malnati M.S., Poli G., and Clerici M. Preparing for phase II/III HIV vaccine in Africa. *Microbes and Infect.*, 7:1436-1444, 2005.

Zhao J., Voltan R., Peng B., Davis-Warren A., Kalyanaraman V.S., Alvord W.G., Aldrich K., Bernasconi D., Buttò S., Cafaro A., Ensoli B., and Robert-Guroff M. Enhanced cellular immunity to SIV Gag following co-administration of Adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. *Virology*, 342:1-12, 2005.

2006

Olivetta E., and Federico M. HIV-1 Nef protects human monocyte-derived macrophages from HIV-1 induced apoptosis. *Exp Cell Res.*, 312:890-900, 2006.

Bona R., Andreotti M., Buffa V., Leone P., Galluzzo C.M., Amici R., Palmisano L., Mancini M.G., Michelini Z., Di Santo R., Costi R., Roux A., Pommier Y., Marchand C., Vella S., and Cara A. Development of a human immunodeficiency virus vector-based, single-cycle assay for evaluation of anti-integrase compounds. *Antimicrob. Agents Chemother.*, 50:3407-3417, 2006.

Borsutzky S., Ebensen T., Link C., Daniel Becker P., Fiorelli V., Cafaro A., Ensoli B., and Guzmán C.A. Efficient systemic and mucosal responses against the HIV-1 Tat protein by Prime/Boost vaccination using the lipopeptide MALP-2 as adjuvant. *Vaccine*, 24:2049-2056, 2006.

Bozac A., Berto E., Vasquez F., Grandi P., Caputo A., Manservigi R., Ensoli B., and Marconi P. Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses. *Vaccine*, 24:7148-7158, 2006.

Buffa V., Negri D.R., Leone P., Borghi M., Bona R., Michelini Z., Compagnoni D., Sgadari C., Ensoli B., and Cara A. Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo. *Viral Immunol.*, 19:690-701, 2006.

Buffa V., Negri D.R.M., Leone P., Bona R., Borghi M., Bacigalupo I., Carlei D., Sgadari C., Ensoli B., and Cara A. A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)HXB2 Rev/Env or codon-optimized HIV-1JR-FL gp120 generates durable immune responses in mice. *J. Gen. Virol.* 87:1625-1634, 2006.

Cafaro A., Fanales-Belasio E., Moretti S., Fiorelli V., Pavone-Cossut M.R., Tripiciano A., Ferrantelli F., Olivieri E., Nappi F., Macchia I., Monini P., and Ensoli B. Native Tat preferentially enters dendritic cells inducine tumor necrosis factor- α mediated Th1-polarized maturation and immune responses in monkeys and humans. In: *Antiviral Ther.* 11 (Suppl. 2), International Medical Press, pag. 83, 2006 – from the: “AIDS Vaccine 2006 Conference”, Amsterdam, The Netherlands (August 29- September 1, 2006).

Castaldello A., Brocca-Cofano E., Voltan R., Triulzi C., Altavilla G., Laus M., Sparnacci K., Balestri M., Tondelli L., Fortini C., Gavioli R., Ensoli B., and Caputo A. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. *Vaccine*, 24:5655-5669, 2006.

Demberg T., Florese R.H., Gomez-Roman V.R., Larsen K., Van Rompay K.K., Marthas M.L., Venzon D., Kalyanaraman V., Pal R., Barnett S.W., Cafaro A., Ensoli B., and Robert-Guroff M. Non-neutralizing antibodies and vaccine-induced protection. *Retrovirology*, 3(Suppl 1):S26, 2006.

Ensoli B. The use of HAART for biological tumour therapy. *J. HIV Ther.*, 11:53-56, 2006.

Ensoli B., Fiorelli V., Ensoli F., Cafaro A., Titti F., Buttò S., Monini P., Magnani M., Caputo A., and Garaci E. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. *AIDS*, 20:2245–2261, 2006.

Ensoli B., Fiorelli V., Longo O., Bellino S., Ensoli F., Tripiciano A., Scoglio A., Ruiz M., Collacchi B., Francavilla V., Lazzarin A., Tambussi G., Visintini R., Narciso P., D'Offizi G., Giulianelli M., Carta M., Di Carlo A., Palamara G., and Giuliani M. Prophylactic and therapeutic Phase I trials with the active Tat protein vaccine: results of the interim analysis. In: *Antiviral Ther.* 11 (Suppl. 2), International Medical Press, pag. 79, 2006 – from the: “AIDS Vaccine 2006 Conference”, Amsterdam, The Netherlands (August 29- September 1, 2006).

Ensoli B., Wahren B., Le Grand R., Gavioli R., Guzman C.A., Magnani M., Stanescu I., Erfle V., Barnett S., Gotch F., Vardas E., Glashoff R., Clerici M., Poli G., Holmes H., and Caputo A. AIDS Vaccine Integrated Project (AVIP): a consortium funded by the FP-6 EU program. In: *Antiviral Ther.* 11 (Suppl. 2), International Medical Press, pag. 157, 2006 – from the: “AIDS Vaccine 2006 Conference”, Amsterdam, The Netherlands (August 29- September 1, 2006).

Ensoli F., Fiorelli V., Tripiciano A., Scoglio A., Collacchi B., Ruiz-Alvarez M., Fazio A., Panicci G., Arancio A., Stivali F., Francavilla V., Longo O., Buttò S., Poli G., and Ensoli B. Anti-Tat humoral and cellular immunity in HIV-1 infected patients, including asymptomatic individuals and LTNP, aimed at identifying immune correlates of protection which are key to vaccine development. In: *Antiviral Ther.* 11 (Suppl. 2), International Medical Press, pag. 140, 2006 – from the: “AIDS Vaccine 2006 Conference”, Amsterdam, The Netherlands (August 29- September 1, 2006).

Ferrantelli F., Buttò S., Cafaro A., Wahren B., and Ensoli B. Building Collaborative Networks for HIV/AIDS Vaccine Development: the AVIP experience. *Springer Semin. Immunopathol.*, 28:289-301, 2006.

Garrafa E., Alessandri G., Benetti A., Turetta D., Corradi A., Cantoni A.M., Cervi E., Bonardelli S., Parati E., Giulini S.M., Ensoli B., and Caruso A. Isolation and characterization of lymphatic microvascular endothelial cells from human tonsils. *J. Cell. Physiol.*, 207:107-113, 2006.

Goletti D., Macchia I., Leone P., Pace M., Sernicola L., Pavone-Cossut M.R., Maggiorella M.T., Cafaro A., Ensoli B., and Titti F. Innate anti-viral immunity is associated with the protection elicited by the Simian Immunodeficiency Virus (SIV) live attenuated virus vaccine in cynomolgus monkeys. *Med. Sci. Monit.*, 12:BR330-340, 2006.

Masella R., Vari R., D'Archivio M., Santangelo C., Scazzocchio B., Maggiorella M.T., Sernicola L., Titti F., Sanchez M., Di Mario U., Leto G., and Giovannini C. Oxidised LDL modulate adipogenesis in 3T3-L1 preadipocytes by affecting the balance between cell proliferation and differentiation. *FEBS Lett.*, 580:2421-2429, 2006.

Muratori C., D'Aloja P., Superti F., Tinari A., Sol-Foulon N., Sparacio S., Bosch V., Schwartz O. and Federico M. Generation and characterization of a stable cell population releasing fluorescent HIV-1-based Virus Like Particles in an inducible way. *BMC Biotechnol.*, 6:52, 2006.

Negri D.R., Borghi M., Baroncelli S., Macchia I., Buffa V., Sernicola L., Leone P., Titti F., and Cara A. Identification of a cytotoxic T-lymphocyte (CTL) epitope recognized by Gag-specific CTLs in cynomolgus monkeys infected with simian/human immunodeficiency virus. *J. Gen. Virol.* 87:3385-3392, 2006.

Pardini M., Giannoni F., Palma C., Iona E., Cafaro A., Brunori L., Rinaldi Monica, Fazio Vito, Laguardia M., Carbonella C., Magnani M., Ensoli B., Fattorini L., and Cassone A. Immune response and protection by DNA vaccines expressing antigen 85B of *Mycobacterium tuberculosis*. *FEMS Microbiol. Lett.*, 262:210-215, 2006.

Peretti S., Schiavoni I., Pugliese K., and Federico M. Selective elimination of HIV-1 infected cells by Env-directed, HIV-1 based Virus Like Particles. *Virology*, 345:115-126, 2006.

Remoli A.L., Marsili G., Pernotti E., Gallerani E., Ilari R., Nappi F., Cafaro A., Ensoli B., Gavioli R., and Battistini A. Intracellular HIV-1 tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. *Biochem. J.*, 396:371-380, 2006.

Ribechini E., Fortini C., Marastoni M., Traniello S., Spisani S., Monini P., and Gavioli R. Identification of CD8+ T cell epitopes within lytic antigens of human herpes virus 8. *J Immunol.*, 176:923-930, 2006.

Sgadari C., Toschi E., Bacigalupo I., Sabbatucci M., Palladino C., Carlei D., Barillari G., and Ensoli B. Patogenesi del Sarcoma di Kaposi. In: *Tumori ed Infezioni da HIV. Patogenesi e studi clinici del GICAT (Italian)*. Milano: Biomedica, pp. 15-26, 2006.

Simonelli C., Talamini R., Bearz A., Berretta M., Spazzapan S., Monini P., Sgadari C., Sartor I., Ensoli B., and Tirelli U. Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma. *Ann. Oncol.*, 17:1335-1336, 2006.

Titti F., Borsetti A., Baroncelli S., Maggiorella M.T., Moretti S., Sernicola L., Belli R., Ridolfi B., Catone S., Farcomeni S., Negri D.R.M., Cafaro A., and Ensoli B. Viral outcome of Simian-Human Immunodeficiency Virus SHIV-89.6P adapted in cynomolgus monkeys (SHIV-89.6 Pcy243). In: *Antiviral Ther.* 11 (Suppl. 2), International Medical Press, pag. 189, 2006 – from the: “AIDS Vaccine 2006 Conference”, Amsterdam, The Netherlands (August 29- September 1, 2006).

Titti F., Ferrantelli F., Olivieri E., Farcomeni S., Leone P., Macchia I., Maggiorella T., Borsetti A., Cafaro A., Srivastava I., Monini P., Barnett S., and Ensoli B. A novel HIV/AIDS vaccine based on the combination of HIV Tat and $\Delta V2$ -Env proteins: preclinical studies. In: *Antiviral Ther.* 11 (Suppl. 2), International Medical Press, pag. 139, 2006 – from the: “AIDS Vaccine 2006 Conference”, Amsterdam, The Netherlands (August 29- September 1, 2006).

Titti F., Maggiorella M.T., Sernicola L., Crostarosa F., Belli R., Pavone-Cossut M.R., Macchia I., Farcomeni S., Tenner-Racz P.K., Racz P., and Ensoli B. Protective efficacy of multiprotein genetic vaccine in the SIV-macaca animal model. In: *Antiviral Ther.* 11 (Suppl. 2), International Medical Press, pag. 188, 2006 – from the: “AIDS Vaccine 2006 Conference”, Amsterdam, The Netherlands (August 29- September 1, 2006).

Toschi E., Bacigalupo I., Strippoli R., Cereseto A., Falchi M., Chiozzini C., Nappi F., Sgadari C., Barillari G., Mainiero F., and Ensoli B. HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway. *Mol. Biol. Cell*, 17:1985-1994, 2006.

2007

Bona R., Macchia I., Baroncelli S., Negri D.R., Leone P., Pavone-Cossut M.R., Catone S., Buffa V., Ciccozzi M., Heeney J., Fagrouch Z., Titti F., and Cara A. T cell receptor excision circles (TRECs) analysis during acute intrarectal infection of cynomolgus monkeys with pathogenic chimeric simian human immunodeficiency virus. *Virus Res.*, 126:86-95, 2007.

Bråve A., Hinkula J., Cafaro A., Eriksson L.E., Srivastava I.K., Magnani M., Ensoli B., Barnett S.W., Wahren B., and Rollman E. Candidate HIV-1 gp140ΔV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. *Vaccine*, 25:6882-6890, 2007.

Demberg T., Florese R.H., Heath M.J., Larsen K., Kalisz I., Kalyanaraman V.S., Lee E.M., Pal R., Venzon D., Grant R., Patterson L.J., Koriath-Schmitz B., Buzby A., Dombagoda D., Montefiori D.C., Letvin N.L., Cafaro A., Ensoli B., and Robert-Guroff M. A replication-competent Ad-HIVtat and -HIVenv priming/1 Tat and Envelope protein boosting regimen elicits enhanced protective efficacy against SHIV89.6P challenge in rhesus macaques. *J. Virol.*, 81:3414-3427, 2007.

Ensoli B. AIDS Vaccine Integrated project (AVIP): a Consortium funded by the FP-6 EU Program. In: *The Parliament Magazine*, Issue 257, November 26th 2007.

Federico M. The outstanding role of Nef in the response of macrophage to HIV infection. In "HIV and the macrophage", Transworld Research Network, Editor: G. Herbein, 2007.

Fiorucci G., Olivetta E., Chiantore M.V., and Federico M. Microarray Analysis Reveals CCL24/Eotaxin-2 as an Effector of the Pathogenetic effects Induced by HIV-1 Nef. *Curr. Drug Discov. Technol.*, 4:12-23, 2007.

Maggiorella M.T., Sernicola L., Crostarosa F., Belli R., Pavone-Cossut M.R., Macchia I., Tenner-Racz K., Racz P., Ensoli B., and Titti F. Multiprotein Genetic Vaccine in the SIV-Macaca animal model: a promising approach to generate sterilising immunity to HIV infection. *J. Med. Primatol.*, 36:180-194, 2007.

Mangino G., Percario Z.A., Fiorucci G., Vaccari G., Manrique S., Romeo G., Federico M., Geyer M, and Affabris E. In vitro treatment of human monocyte/macrophages with myristoylated recombinant Nef of HIV-1 leads to the activation of MAPKs, I κ B kinases and Interferon Regulatory Factor 3 and to the release of Beta Interferon. *J. Virol.*, 81:2777-2791, 2007.

Muratori C., Sistigu A., Ruggiero E., Falchi M., Bacigalupo I., Palladino C., Toschi E., and Federico M. Macrophages Transmit Human Immunodeficiency Type 1 Products to CD4 Negative Cells: Involvement of Matrix Metalloproteinase-9. *J. Virol.* 81:9078-9087, 2007.

Negri D.R., Michelini Z., Baroncelli S., Spada M., Vendetti S., Buffa V., Bona R., Leone P., Klotman M.E., and Cara A. Successful immunization with a single injection of non-integrating lentiviral vector. *Mol. Ther.*, 15:1716-1723, 2007.

Puppo M., Bosco M.C., Federico M., Pastorino S., Varesio L. Hypoxia inhibits Moloney murine leukemia virus expression in activated macrophages. *J. Leukoc. Biol.*, 81:528-538, 2007.

Sirianni M.C., Campagna M., Scaramuzzi D., Carbonari M., Toschi E., Bacigalupo I., Monini P., and Ensoli B. Control of human herpes virus type 8-associated diseases by NK cells. *Ann. N.Y. Acad. Sci.*,1096:37-43, 2007.

Titti F., Cafaro A., Ferrantelli F., Tripiciano A., Moretti S., Caputo A., Gavioli R., Ensoli F., Robert-Guroff M., Barnett S., and Ensoli B. Problems and emerging approaches in HIV/AIDS vaccine development. *Exp. Opin. Emerg. Drugs*, 12:23-48, 2007.

Voltan R., Castaldello A., Brocca-Cofano E., Altavilla G., Caputo A., Laus M., Sparnacci K., Ensoli B., Spaccasassi S., Ballestri M., and Tondelli L. Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes. *Pharm. Res.*, 24:1870-1882, 2007.

2008

Borsetti A., Baroncelli S., Maggiorella M.T., Bellino S., Moretti S., Sernicola L., Belli R., Ridolfi B., Farcomeni S., Negri D.R.M., Cafaro A., Ensoli B., and Titti F. Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. *Arch. Virol.*, in press.

Cafaro A., Macchia I., Maggiorella M.T., Titti F., and Ensoli B. Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS. *Mol. Biotechnol.*, in press.

Dehò L., Walwema R., Cappelletti A., Sukati H., Nsibandze D., Almaviva M., Buttò S., Ensoli B., Galli M., and Balotta C. Characterization of human immunodeficiency virus type 1 from antiretroviral drug-naïve population in Swaziland. *AIDS Res. Hum. Retrovir.*, in press.

Ensoli B., Nappi F., Ferrantelli F. and Buttò S. Meccanismo di infezione dei virus dell'immunodeficienza acquisita (HIV-1, HIV-2, SIV). *Enciclopedia Medica Italiana (Third Update, II Edition)*, in press.

Gavioli R., Cellini S., Castaldello A., Voltan R., Gallerani E., Gagliardoni F., Fortini C., Brocca-Cofano E., Triulzi C., Cafaro A., Srivastava I., Barnett S., Caputo A., and Ensoli B. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS. *Vaccine*, 26:727-737, 2008.

Gudmundsdottir L., Bernasconi D., Hejdeman B., Sandstrom E., Alaeus A., Lidman K., Ensoli B., Wahren B., and Buttò S. Cross clade immune responses to gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles. *Vaccine*, in press.

Ridolfi B., Genovese D., Argentini C., Maggiorella M.T., Sernicola L., Buttò S., Titti F., Borsetti A., and Ensoli B. Tat protein vaccination of cynomolgus macaques influences SHIV-89.6Pcy243 epitope variability. *Virus Genes*, in press.

Sgarbanti M., Remoli A.L., Marsili G., Ridolfi B., Borsetti A., Perrotti E., Orsetti R., Ilari R., Sernicola R., Stellacci E., Ensoli B., Battistini A. IRF-1 is required for full NF- κ B transcriptional activity at the HIV-1 LTR enhancer. *J. Virol.*, in press

Suligoi B., Buttò S., Galli C., Bernasconi D., Salata R.A., Tamoschi L., Chiappi M., Mugenyi P., Pimpinelli F., Kityo C., Regine V, Rezza G. Detection of recent HIV infections in African individuals infected by HIV-1 non-B subtypes using HIV antibody avidity. *J. Clin. Virol.*, in press.